These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12510136)

  • 21. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders.
    Anselme F; Moubarak G; Savouré A; Godin B; Borz B; Drouin-Garraud V; Gay A
    Heart Rhythm; 2013 Oct; 10(10):1492-8. PubMed ID: 23811080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac dysfunction and prolonged hemodynamic deterioration after implantable cardioverter-defibrillator shock in patients with systolic heart failure.
    Toh N; Nishii N; Nakamura K; Tada T; Oe H; Nagase S; Kohno K; Morita H; Kusano KF; Ito H
    Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):898-905. PubMed ID: 22837155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term clinical outcome in patients with severe left ventricular dysfunction and an implantable cardioverter-defibrillator after ventricular tachyarrhythmias.
    Pelicano N; Oliveira M; Da Silva N; Antunes E; Santos S; Conceição JM; Roquette J; Quininha J
    Rev Port Cardiol; 2005 Apr; 24(4):487-98. PubMed ID: 15977773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Left ventricular function improvement after prophylactic implantable cardioverter-defibrillator implantation in patients with non-ischaemic dilated cardiomyopathy.
    Grimm W; Timmesfeld N; Efimova E
    Europace; 2013 Nov; 15(11):1594-600. PubMed ID: 23639855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defibrillation testing in everyday medical practice during implantable cardioverter defibrillator implantation in France: analysis from the LEADER registry.
    Sadoul N; Defaye P; Mouton E; Bizeau O; Dupuis JM; Blangy H; Delarche N; Blanc JJ; Lazarus A;
    Arch Cardiovasc Dis; 2013 Nov; 106(11):562-9. PubMed ID: 24200925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of ventricular arrhythmia burden, therapeutic interventions, and survival, in patients < 75 and patients >or= 75 years of age treated with implantable cardioverter defibrillators.
    Ermis C; Zhu AX; Vanheel L; Sakaguchi RN; Lurie KG; Lu F; Benditt DG
    Europace; 2007 May; 9(5):270-4. PubMed ID: 17371804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dyssynchrony and the risk of ventricular arrhythmias.
    Kutyifa V; Pouleur AC; Knappe D; Al-Ahmad A; Gibinski M; Wang PJ; McNitt S; Merkely B; Goldenberg I; Solomon SD; Moss AJ; Zareba W
    JACC Cardiovasc Imaging; 2013 Apr; 6(4):432-44. PubMed ID: 23579010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sudden death in implantable cardioverter-defibrillator recipients: clinical context, arrhythmic events and device responses.
    Pires LA; Lehmann MH; Steinman RT; Baga JJ; Schuger CD
    J Am Coll Cardiol; 1999 Jan; 33(1):24-32. PubMed ID: 9935004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implantable cardioverter-defibrillator therapy: influence of left ventricular function on long-term results.
    Pitschner HF; Neuzner J; Himmrich E; Liebrich A; Jung J; Heisel A
    J Interv Card Electrophysiol; 1997 Nov; 1(3):211-20. PubMed ID: 9869974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter experience with a pectoral unipolar implantable cardioverter-defibrillator. Active Can Investigators.
    Bardy GH; Yee R; Jung W
    J Am Coll Cardiol; 1996 Aug; 28(2):400-10. PubMed ID: 8800117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in amiodarone efficacy in relation to ejection fraction and basal rhythm in patients with implantable cardioverter defibrillators.
    Watanabe T; Inoue K; Kashiwase K; Mine T; Hirooka K; Shutta R; Mizuno H; Okuyama Y; Sakata Y; Nanto S;
    J Electrocardiol; 2018; 51(6):1111-1115. PubMed ID: 30497740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator.
    Duncker D; Haghikia A; König T; Hohmann S; Gutleben KJ; Westenfeld R; Oswald H; Klein H; Bauersachs J; Hilfiker-Kleiner D; Veltmann C
    Eur J Heart Fail; 2014 Dec; 16(12):1331-6. PubMed ID: 25371320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do implantable cardioverter defibrillators improve survival in patients with severe left ventricular systolic dysfunction after coronary artery bypass graft surgery?
    Fazal IA; Bates MG; Matthews IG; Turley AJ
    Interact Cardiovasc Thorac Surg; 2011 Jun; 12(6):1010-6. PubMed ID: 21398652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in mechanisms and outcomes of syncope in patients with coronary disease or idiopathic left ventricular dysfunction as assessed by electrophysiologic testing.
    Brembilla-Perrot B; Suty-Selton C; Beurrier D; Houriez P; Nippert M; de la Chaise AT; Louis P; Claudon O; Andronache M; Abdelaal A; Sadoul N; Juillière Y
    J Am Coll Cardiol; 2004 Aug; 44(3):594-601. PubMed ID: 15358027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Left ventricular sphericity index analysis for the prediction of appropriate implantable cardioverter-defibrillator therapy.
    Anvari S; Akbarzadeh MA; Bayat F; Namazi MH; Safi M
    Pacing Clin Electrophysiol; 2018 Sep; 41(9):1192-1196. PubMed ID: 29931684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Left Ventricular Ejection Fraction Predicts Severity of Posttraumatic Stress Disorder in Patients With Implantable Cardioverter-Defibrillators.
    Sawatari H; Ohkusa T; Rahamawati A; Ishikawa K; Tsuchihashi-Makaya M; Ohtsuka Y; Nakai M; Miyazono M; Hashiguchi N; Chishaki H; Sakurada H; Mukai Y; Inoue S; Sunagawa K; Chishaki A
    Clin Cardiol; 2016 May; 39(5):263-8. PubMed ID: 27153459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized controlled clinical trial comparing ventricular fibrillation detection time between two transvenous defibrillator models. The Acute Ventak AV investigator group.
    Kühlkamp V; Mortensen P; Kirstein P; den Dulk K; Hoffman E; Wilber D; Higgins S; Kühl M
    Pacing Clin Electrophysiol; 1999 Jul; 22(7):990-8. PubMed ID: 10456626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long Detection Programming in Single-Chamber Defibrillators Reduces Unnecessary Therapies and Mortality: The ADVANCE III Trial.
    Gasparini M; Lunati MG; Proclemer A; Arenal A; Kloppe A; Martínez Ferrer JB; Hersi AS; Gulaj M; Wijffels MCE; Santi E; Manotta L; Varma N
    JACC Clin Electrophysiol; 2017 Nov; 3(11):1275-1282. PubMed ID: 29759624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.
    Duncker D; König T; Hohmann S; Bauersachs J; Veltmann C
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.